p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction

Human Pathology

Volumn 27, Issue 11, 1996, Pages 1211-1220

  Moskaluk, Christopher A ^a   Heitmiller, Richard ^b   Zahurak, Marianna ^b   Schwab, Donna ^b   Sidransky, David ^b   Hamilton, Stanley R ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Barrett esophagus; esophageal neoplasms; p53; WAF 1

Indexed keywords

CYCLIN DEPENDENT KINASE; GENE PRODUCT; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS INJURY; FEMALE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE;

EID: 0029904780     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90317-2     Document Type: Article

References (54)

1. Haggitt RC: Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol 25:982-993, 1994
2. Spechler SJ: Barrett's esophagus. Gastroenterologist 2:273-284, 1994
3. Hamilton SR, Smith RRL: The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 87:301-312, 1987
4. Hameetemah W, Tytgat GNJ, Houthoff HJ, et al: Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroeterology 96:1249-1256, 1989
5. Wang HH, Antonioli DA, Goldman H: Comparative features of esophageal and gastric adenocarcinomas: Recent changes in type and frequency. Hum Pathol 17:482-487, 1986
6. Golematis B, Tzardis P, Hatzikostas P, et al: Changing pattern of distribution of carcinoma of the stomach. Br J Surg 77:63-64, 1990
7. Craanen ME, Dekker W, Blok P, et al: Time trends in gastric carcinoma: Changing patterns of type and location. Am J Gastroenterol 87:572-579, 1992
8. Weinberg RA: The integration of molecular genetics into cancer management. Cancer 70:1653-1658, 1992 (suppl)
9. Knudson AG: All in the (cancer) family. Nature Genet 5:103-104, 1993
10. Hamilton SR: The molecular genetics of colorectal neoplasia. Gastroeterology 105:3-7, 1993
11. Lee JM, Bernstein A: Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metastasis Rev 14:149-161, 1995
12. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
13. Macgeoch C, Barnes DM, Newton JA, et al: p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 11:239-250, 1993
14. Peng H-Q, Hogg D, Malkin D, et al: Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53:3574-3578, 1993
15. Kennedy SM, Macgeogh C, Jaffe R, et al: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutation. Hum Pathol 25:438-442, 1994
16. Moll JM, LaQuaglia M, Bernard J, et al: Wild type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 92:4407-4411, 1995
17. Hall PA, Lane DP: P53 in tumor pathology: Can we trust immunohistochemistry? revisited! J Pathol 172:1-4, 1994 (editorial)
18. El-Diery WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of tumor suppression. Cell 75:817-825, 1993
19. El-Deiry WS, Tokino T, Waldman T, et al: Topological control of p21WAF1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995
20. Casson AG, Mukhopadhyay T, Cleary KR, et al: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51:4495-4499, 1991
21. Casson AG, Monolopoulos B, Troster M, et al: Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 167:52-57, 1994
22. Moore JH, Lesser EJ, Erdody DH, et al: Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 56:487-493, 1994
23. Matozaki T, Sakamoto C, Matsuda K, et al: Mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 182:215-223, 1992
24. Blount PL, Ramel S, Raskind WH, et al: 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 51:5482-5486, 1991
25. Jankowski J, Coghill G, Hopwood D, et al: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33:1033-1038, 1992
26. Flejou J-F, Potet F, Muzeau F, et al: Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 46:330-333, 1993
27. Younes M, Lebovitz RM, Lechago LV, et al: p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: A follow-up study. Gastroenterology 105:1637-1642, 1993
28. Hardwick RH, Shepherd NA, Moorghen M, et al: Adenocarcinoma arising in Barrett's oesophagus: Evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 35:764-768, 1994
29. Flejou J-F, Paraf F, Potet F, et al: P53 protein expression in Barrett's adenocarcinoma: A frequent event with no prognostic significance. Histopathology 24:487-484, 1994
30. Hamelin R, Flejou J-F, Muzeau F, et al: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107:1012-1018, 1994
31. Symmans PJ, Linehan JM, Brito MJ, et al: P53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 173:221-226, 1994
32. Rice TW, Goldblum JR, Falk GW, et al: P53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 108:1132-1137, 1994
33. Jones DR, Davidson AG, Summers CL, et al: Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 57:598-603, 1994
34. Krishnadath KK, Tilanus HW, van Blankenstein M, et al: Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 175:175-180, 1995
35. Flejou J-F, Muzeau F, Potet F, et al: Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract 190:1141-1148, 1994
36. Duhaylongsod FG, Gottfried MR, Iglehart JD, et al: The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221:677-684, 1995
37. Hamilton SR, Smith RRL, Cameron JL: Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. HUM PATHOL 19:942-948, 1988
38. Hermanek P, Sobin LH, (eds): TNM Classification of Malignant Tumours, International Union Against Cancer (UICC) (Ed. 4, Rev 2). Springer-Verlag, 1992.
39. Baas IO, Mulder J-W, Offerhaus GJA, et al: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12, 1994
40. Oyasu R, Nan L, Szumel RC, et al: P53 gene mutations in human urothelial carcinomas: Analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 8:170-176, 1995
41. Sidransky D, Von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991
42. Boyle JO, Koch W, Hruban RH, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993
43. Cox DR: The analysis of binary data. London, Methuen, 1970
44. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
45. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
46. Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34:187-220, 1972
47. Spechler SJ, Zeroogian JM, Antonioli DA, et al: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344:1533-1536, 1994
48. Meltzer SJ, Yin J, Huang Y, et al: Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A 88:4976-4980, 1991
49. Huang Y, Boynton RF, Blount PL, et al: Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52:6525-6530, 1991
50. Blount PL, Meltzer SJ, Yin J, et al: Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A 90:3221-3225, 1993
51. Michieli P, Chedid M, Lin D, et al: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395, 1994
52. Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1026, 1995
53. Clark GWB, Smyrk TC, Burdiles P, et al: Is Barrett's metaplasia the source of adenocarcinoma of the cardia? Arch Surg 129:609-614, 1994
54. Paraf F, Flejou J-F, Pignon J-P, et al: Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol 19:183-191, 1995